ALDA Pharmaceuticals Corp.
OTCQB – mid-tier listing : APCSF

ALDA Pharmaceuticals Corp.

May 26, 2011 11:40 ET

ALDA Enters National Phase with New Patent Application

VANCOUVER, BRITISH COLUMBIA--(Marketwire - May 26, 2011) - ALDA Pharmaceuticals Corp. (TSX VENTURE:APH)(OTCQB:APCSF) (the "Company" or "ALDA") has filed its patent application, "Antiseptic Compositions for the Treatment of Infections", with the US Patent and Trademark Office (Serial #12/933,358). The application, first submitted to the Canadian Intellectual Property office for review in March, 2008 under the Patent Cooperation Treaty, seeks protection for the composition and preparation of T36® formulations that also contain steroids, anesthetics or analgesics for use on topical infections and, in particular, inflamed infections. Typically, infections with associated inflammation are treated with separate antiseptic and anti-inflammatory preparations. The new T36® formulations combine these properties into a single treatment, making the prescription process easier for the physician and the application easier for the patient. Submissions to the European and Canadian patent offices are also planned. This patent is the third in a series of patents providing protection for the T36® technology that have been issued or are pending.

The first patent, providing protection for the composition and production methods for ALDA's T36® formulation until August 20, 2022, is:

  • issued in Australia (#2002322916), the US (#7,338,927) and China (#ZL02829642.7),
  • allowed and pending in Canada (Patent Application #2,495,938) and
  • pending in the EU (Patent Application #02754054.1-2113).

The second patent, providing protection for the use of T36® as a component of a personal lubricant, in a method of preventing or reducing the transmission of a sexually transmitted diseases including Herpes, Chlamydia and HIV and for use in sanitizers and cleansers in creams, ointments and wipes until August 20, 2022, is:

  • issued in Australia (#2007237333) and the US (#7,560,422),
  • allowed and is pending in Canada (Patent Application #2,495,938) and
  • pending in China (Chinese Divisional Patent Application #200710142798.3) and the EU (Patent Application #02754054.1-2113).

According to Dr. Terrance Owen, President & CEO, "Intellectual property protection is one of the key assets of emerging pharmaceutical companies. We are committed to building the Company's patent portfolio so that we have the protection required in the main international markets that we are targeting with the therapeutic products derived from the T36® technology."

About ALDA Pharmaceuticals Corp.

ALDA is focused on the development of infection-control therapeutics derived from its patented T36® technology. The company trades on the TSX Venture Exchange under the symbol APH and on the OTCQB under the symbol APCSF. The Company was the Official Supplier to the Vancouver 2010 Olympic Winter Games and the Vancouver 2010 Paralympic Winter Games and is the Official Supplier to the Canadian Olympic Committee, the 2010 Canadian Olympic Team and the 2012 Canadian Olympic Team for antiseptic hand sanitizer, disinfectant and disinfectant cleaning products. The Company was also selected as one of the TSX Venture 50 companies in the Technology and Life Sciences sector for 2010.

Terrance G. Owen, Ph.D., MBA, President & CEO

ALDA Pharmaceuticals Corp.

Cautionary Note Regarding Forward-looking Statements: Information in this press release that involves ALDA's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. ALDA generally uses words such as "outlook", "will", "could", "would", "might", "remains", "to be", "plans", "believes", "may", "expects", "intends", "anticipates", "estimate", "future", "plan", "positioned", "potential", "project", "remain", "scheduled", "set to", "subject to", "upcoming", and similar expressions to help identify forward-looking statements. The forward-looking statements in this release are based upon information available to ALDA as of the date of this release, and ALDA assumes no obligation to update any such forward-looking statements. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of ALDA and are subject to risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Contact Information